 Intra-Cellular Therapies NASDAQ:ITCI was downgraded by equities researchers at BidaskClub from a buy rating to a hold rating in a research report issued to clients and investors on Tuesday, BidAskClub reports. Other equities analysts have also recently issued research reports about the company. Zacks Investment Research cut Intra-Cellular Therapies from a buy rating to a ... 